Technology Insight: Advances in molecular imaging and an appraisal of PET/CT scanning

Nature Clinical Practice Cardiovascular Medicine

Volumn 5, Issue 3, 2008, Pages 160-170

  Weber, Wolfgang A ^a   Grosu, Anca L ^a   Czernin, Johannes ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CT; Molecular imaging; Multimodality imaging; PeT; PeT CT

Indexed keywords

CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ECONOMIC ASPECT; HEALTH CARE SYSTEM; HUMAN; MEDICAL TECHNOLOGY; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; BRAIN CANCER; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; DRUG RESPONSE; ESOPHAGUS CANCER; FALSE POSITIVE RESULT; GASTROINTESTINAL STROMAL TUMOR; GLIOMA; HEAD AND NECK CANCER; HEALTH ECONOMICS; HISTOPATHOLOGY; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE PROCESSING; IMAGE QUALITY; INTERMETHOD COMPARISON; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MULTIPLE CYCLE TREATMENT; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT CARE PLANNING; PROSTATE CANCER; RADIATION ATTENUATION; RADIATION EXPOSURE; RADIOSENSITIVITY; SOLID TUMOR; THREE DIMENSIONAL IMAGING; WHOLE BODY RADIATION;

DRUG MONITORING; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; SENSITIVITY AND SPECIFICITY; SYSTEMS INTEGRATION; TOMOGRAPHY, X-RAY COMPUTED;

2 NITROIMIDAZOLE; ANTINEOPLASTIC AGENT; ARABINOSIDE; CONTRAST MEDIUM; COPPER 60; FLUORODEOXYGLUCOSE F 18; IMATINIB; METHYLTHIOSEMICARBAZONE; RADIOISOTOPE;

EID: 40249110181     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncponc1041     Document Type: Review

References (69)

1. Phelps M et al. (1975) Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med 16: 210-224
2. Reivich M et al. (1977) Measurement of local cerebral glucose metabolism in man with 18F-2-fluoro-2-deoxy-d-glucose. Acta Neurol Scand Suppl 64: 190-191
3. Schelbert H et al. (1979) Regional myocardial perfusion assessed with N-13 labeled ammonia and positron emission computerized axial tomography. Am J Cardiol 43: 209-218
4. Som P et al. (1980) A fluorinated glucose analog, 2-fluoro-2-deoxy-d-glucose (F-18): Nontoxic tracer for rapid tumor detection. J Nucl Med 21: 670-675
5. Dahlbom M et al. (1992) Whole-body positron emission tomography: Part I. Methods and performance characteristics. J Nucl Med 33 1191-1199
6. Beyer T et al. (2000) A combined PET/CT scanner for clinical oncology. J Nucl Med 41: 1369-1379
7. Townsend DW et al. (2004) PET/CT today and tomorrow. J Nucl Med 45: 4S-14S
8. IMV (2006) 2005/06 PET Market Summary Report. IMV: Des Plaines. http://www.imvinfo.com/index.asp?sec=mkt&sub=omkt&pag= def&pid=42010
9. Halpern B et al. (2004) Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability. J Nucl Med 45: 797-801
10. Kim J-H et al. (2005) Comparison between 18F-FDG PET, in-line PET/ CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med 46: 587-595
11. Czernin J et al. (2007) Improvements in cancer staging with PET/ CT: Literature-based evidence as of September 2006. J Nucl Med 48 Suppl 1: 78S-88S
12. Zasadny K et al. (1996) Untreated lung cancer: Quantification of systematic distortions of tumor size and shape on non-attenuation corrected 2-[fluorine-18] fluoro-2-deoxy-d-glucose PET scans. Radiology 200: 135-141
13. Kinahan P et al. (1998) Attenuation correction for a combined 3D PET/CT scanner. Med Phys 25: 2046-2053
14. Goerres G et al. (2002) PET-CT image co-registration in the thorax: Influence of respiration. J Nucl Med 29: 351-360
15. Pan T et al. (2005) Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med 46: 1481-1487
16. Nehmeh SA et al. (2004) Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys 31: 3179-3186
17. Antoch G et al. (2002) Focal tracer uptake: A potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med 43 1339-1342
18. Antoch G et al. (2004) To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med 45 (Suppl): S56-S65
19. Allen-Auerbach M et al. (2006) Standard PET/CT of the chest during shallow breathing is inadequate for comprehensive staging of lung cancer. J Nucl Med 47: 298-301
20. Schoder H et al. (2006) 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 47: 755-762
21. Palmedo H et al. (2006) Integrated PET/CT in differentiated thyroid cancer: Diagnostic accuracy and impact on patient management. J Nucl Med 47: 616-624
22. Yi CA et al. (2006) Tissue characterization of solitary pulmonary nodule: Comparative study between helical dynamic CT and integrated PET/ CT. J Nucl Med 47: 443-450
23. Kim SK et al. (2007) Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med 48: 214-220
24. Lardinois D et al. (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348: 2500-2507
25. Cerfolio R et al. (2006) Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: A prospective study. J Thorac Cardiovasc Surg 131: 1229-1235
26. Tatsumi M et al. (2006) Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 33: 254-262
27. Fueger B et al. (2005) Performance of 2-deoxy-2-[F-18]fluoro-d-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol 7: 369-376
28. Bar-Shalom R et al. (2005) The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging 32: 918-924
29. Cohade C et al. (2003) Direct comparison of (18)F-FDG PET and PET/ CT in patients with colorectal carcinoma. J Nucl Med 44: 1797-1803
30. Freudenberg LS et al. (2004) FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 31: 325-329
31. Reinhardt MJ et al. (2006) Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: Experience with 250 consecutive patients. J Clin Oncol 24: 1178-1187
32. Cohade C et al. (2003) "USA-Fat": Prevalence is related to ambient outdoor temperature-evaluation with 18F-FDG PET/CT. J Nucl Med 44: 1267-1270
33. Allen-Auerbach M et al. (2004) Comparison between 2-deoxy-2-[18F]fluoro-[D]-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 6: 411-416
34. Dwamena B et al. (1999) Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s - meta-analytic comparison of PET and CT. Radiology 213: 530-536
35. Chen Y et al. (2006) Clinical usefulness of fused PET/CT compared with PET alone or CT alone in nasopharyngeal carcinoma patients. Anticancer Res 26: 1471-1477
36. Schoder H et al. (2004) Head and neck cancer: Clinical usefulness and accuracy of PET/CT image fusion. Radiology 231: 65-72
37. Shim SS et al. (2005) Non-small cell lung cancer: Prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 236: 1011-1019
38. Votrubova J et al. (2006) The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 33 779-784
39. la Fougère C et al. (2006) Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 33: 1417-1425
40. Mottaghy FM et al. (2007) Direct comparison of [(18)F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma. Eur J Nucl Med Mol Imaging 34: 1355-1364
41. Grosu AL et al. (2003) Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C-methionine-PET data for stereotactic radiotherapy using a LINAC: First clinical experience. Int J Radiat Oncol Biol Phys 56: 1450-1463
42. Ling CC et al. (2000) Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 47: 551-560
43. Nestle U et al. (2006) Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): The technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol 81: 209-225
44. Gregoire V et al. (2007) PET-based treatment planning in radiotherapy: A new standard? J Nucl Med 48 (Suppl 1): S68-S77
45. Caldwell CB et al. (2001) Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT. the impact of 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys 51: 923-931
46. Nestle U et al. (2005) Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med 46: 1342-1348
47. Chapman JD et al. (2003) Molecular (functional) imaging for radiotherapy applications: An RTOG symposium. Int J Radiat Oncol Biol Phys 55: 294-301
48. Daisne JF et al. (2004) Tumor volume in pharyngolaryngeal squamous cell carcinoma: Comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 233: 93-100
49. Grosu AL et al. (2005) Positron emission tomography for radiation treatment planning. Strahlenther Onkol 181: 483-499
50. Grosu AL et al. (2005) L-(methyl-11 C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 63 64-74
51. Grosu AL et al. (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63: 511-519
52. Grosu A et al. (2007) Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting using IMRT in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 69: 541-551
53. Chao KS et al. (2001) A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 49: 1171-1182
54. Weber WA (2006) Positron emission tomography as an imaging biomarker. J Clin Oncol 24: 3282-3292
55. Juweid ME and Cheson BD (2005) Role of positron emission tomography in lymphoma. J Clin Oncol 23: 4577-4580
56. Cheson BD et al. (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25: 579-586
57. Larson SM et al. (1999) Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging 2: 159-171
58. Beer AJ et al. (2006) Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy. Radiology 239: 472-480
59. Wieder HA et al. (2005) Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med 46: 2029-2034
60. Pöttgen C et al. (2006) Value of 18F-fluoro-2-deoxy-[D]-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 12: 97-106
61. Goerres GW et al. (2005) The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: Long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 32 153-162
62. Antoch G et al. (2004) Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45: 357-365
63. Reske SN et al. (2006) Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 47: 1249-1254
64. Shields AF et al. (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4: 1334-1336
65. Buck A et al. (2003) Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 44: 1426-1431
66. Beer AJ et al. (2006) Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 12: 3942-3949
67. Larson SM et al. (2004) Tumor localization of 16β-18F-fluoro-5α-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 45: 366-373
68. Linden HM et al. (2006) Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 24: 2793-2799
69. Gabriel M et al. (2007) 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48: 508-518